On July 6, Hims & Hers Health rose 5.14% in regular trading, reaching $38.69 per share with turnover of $1.86 billion, extending gains following a recent analyst upgrade.

The upward momentum follows BofA Securities lifting its price target on the company to $36 from $25 while maintaining a neutral rating, which initially drove shares up over 8% on July 2. The stock has now surpassed that revised target. According to FactSet, the consensus average rating stands at Hold with a mean price target of $29.27, suggesting the market is pricing in optimism beyond current analyst estimates.

Supporting the positive trajectory, Hims & Hers completed its acquisition of Eucalyptus in early June, expanding its consumer health platform across Australia, Canada, Germany, and other international markets. The company also secured a $300 million convertible senior notes offering to fund international expansion and AI-driven platform investment, while modifying its credit agreement to accommodate the acquisition.

Within the Health Care Services sector, performance was mixed. Hinge Health rose 6.63%, BrightSpring Health Services gained 3.55%, Guardant Health added 1.89%, while CVS Health fell 1.77% and The Cigna Group declined 3.02%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)